Drug firm Zydus Cadila on Sunday said it has received DCGI approval to initiate Phase III clinical trials of its COVID-19 vaccine ZyCoV-D.
Drug firm Zydus Cadila on Wednesday said it has received approval from the Drug Controller General of India (DCGI) for Saroglitazar Mg, used for the treatment of non-alcoholic fatty liver disease (NAFLD), in the country.
The Phase-II study of the vaccine, ZyCoV-D, had been conducted in over 1,000 healthy adult volunteers as part of the adaptive Phase-I and II dose escalation, multi-centric, randomised and double-blind placebo controlled study.
Drug firm Zydus Cadila on Monday said it has received permission from Drugs Controller General of India (DCGI) to initiate phase-1 clinical trial of its novel molecule ZYIL1, indicated for use as an inhibitor for inflammation condition 'NLRP3'.
Pfizer India has become the first pharmaceutical firm to seek from the DCGI an emergency use authorisation for its COVID-19 vaccine in the country, after its parent company secured such clearance in the UK and Bahrain.
In a regulatory filing, Zydus Cadila said it has received approval from the DCGI to start the phase 3 clinical trials in COVID-19 patients with its biological therapy Pegylated Interferon alpha-2b or PegiHep.
PM Modi visited Zydus Cadila's manufacturing facility near Ahmedabad, as he began his three-city visit to review ongoing coronavirus vaccine development work.
The PM will be flying back to the national capital after a stopover in Pune, where he will visit the Serum Institute of India (SII), which has partnered with pharma giant AstraZeneca and the Oxford University for the vaccine.
The PM will be flying back to the national capital after a stopover in Pune, where he will visit the Serum Institute of India (SII), which has partnered with pharma giant AstraZeneca and the Oxford University for the vaccine. Earlier in the morning, Modi visited Zydus Cadila''s plant near Ahmedabad.
Wearing a PPE kit, Modi reviewed the vaccine development process at the Zydus Cadila research centre in Changodar industrial area, over 20 km from Ahmedabad.
Earlier in the morning, PM Modi visited Zydus Cadila''s plant near Ahmedabad.
Visited Zydus Biotech Park in Ahmedabad to know more about the indigenous DNA based vaccine being developed by Zydus Cadila. Govt of India is actively working with them to support them in this journey: PM Modi
Prime Minister Narendra Modi landed in Ahmedabad on Saturday as part of his three-city visit to ireview coronavirus vaccine development work at facilities.
The plant is located in the Changodar industrial area, over 20 km from Ahmedabad. Modi will be at the plant for an hour, beginning 9.30 am, PMO said.
Modi will first visit pharma major Zydus Cadila's plant near Ahmedabad to get information about its vaccine development, Gujarat Deputy Chief Minister Nitin Patel said.
Prime Minister Narendra Modi will embark on a three-city visit tomorrow to personally review the coronavirus vaccines development and manufacturing process.
Zydus Cadila on Thursday said it has received tentative approval from the US health regulator to market Linagliptin tablets, used to treat type 2 diabetes in adults.
Drug firm Zydus Cadila on Tuesday said it has received final approval from the US health regulator to market Solifenacin Succinate tablets, used for treatment of overactive bladder.
Drug firm Zydus Cadila on Monday said it has received tentative approval from the US health regulator to market Tofacitinib extended-release tablets, used to treat ulcerative colitis, in the American market.
Zydus Cadila has received tentative approval from the US Food and Drug Administration (USFDA) to market Palbociclib Capsules in the strengths of 75 mg, 100 mg, and 125 mg, Zydus Cadila, part of the Cadila Healthcare group, said in a regulatory filing.
Top News
Latest News
